Download Citation
Article Source:
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Nishioka C,
Tahata Y,
Maesaka K,
Kai M,
Shirai K,
et al.
(2026)
Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.
PLOS ONE 21(5): e0341395.
https://doi.org/10.1371/journal.pone.0341395